Samsung Bioepis submits biologic application of Herceptin biosimilar in U.S.

Published: 2017-12-21 16:30:00
Updated: 2017-12-21 15:06:24

Samsung Bioepis(CEO/President Han-Seung Ko) is getting ready to target the U.S. market followed by the European one with ‘SB3(generic name: trastuzumab, European name: ontruzant),’ a biosimilar for the treatment of breast cancer.

Samsung Bioepis announced the U.S. Food and Drug Administration(FD...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.